Arena Pharmaceuticals, Inc. (ARNA) Posts Q3 Loss of 16c/Sh.

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) reported Q3 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $3.46 million versus the consensus estimate of $3.37 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Movano (MOVE) Misses Q2 EPS by 195c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M